{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T01:33:37Z","timestamp":1785375217022,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.14283\/jpad.2020.51","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T07:48:20Z","timestamp":1614239300000},"page":"68-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparative Analysis of Different Definitions of Amyloid-\u03b2 Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer"],"prefix":"10.1016","volume":"8","author":[{"given":"M.","family":"Mil\u00e0-Alom\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Salvad\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shekari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Grau-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sala-Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"S\u00e1nchez-Benavides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Arenaza-Urquijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Gonz\u00e1lez-de-Ech\u00e1varri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kollmorgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Gispert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Su\u00e1rez-Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.14283\/jpad.2020.51_bib1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","article-title":"Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria","volume":"12","author":"Dubois","year":"2016","journal-title":"Alzheimer's Dement"},{"issue":"4","key":"10.14283\/jpad.2020.51_bib2","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer's Dement"},{"issue":"4","key":"10.14283\/jpad.2020.51_bib3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.14283\/jpad.2019.25","article-title":"Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study","volume":"6","author":"Burnham","year":"2019","journal-title":"J Prev Alzheimer's Dis"},{"key":"10.14283\/jpad.2020.51_bib4","doi-asserted-by":"crossref","first-page":"1756286","DOI":"10.1177\/1756286419888819","article-title":"Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease","volume":"12","author":"Mil\u00e0-Alom\u00e0","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.14283\/jpad.2020.51_bib5","first-page":"181","article-title":"The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations","volume":"1","author":"Cavedo","year":"2014","journal-title":"J Prev Alzheimer's Dis"},{"issue":"3","key":"10.14283\/jpad.2020.51_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer's disease","volume":"13","author":"Jack","year":"2017","journal-title":"Alzheimer's Dement"},{"issue":"5","key":"10.14283\/jpad.2020.51_bib7","first-page":"1","article-title":"A \/ T \/ N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"0","author":"Jack","year":"2016","journal-title":"Neurology"},{"issue":"10","key":"10.14283\/jpad.2020.51_bib8","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","article-title":"Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid \u03b2-Amyloid 42","volume":"71","author":"Palmqvist","year":"2014","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.14283\/jpad.2020.51_bib9","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.23908","article-title":"Comparing positron emission tomography imaging and cerebrospinal fluid measurements of \u03b2-amyloid","volume":"74","author":"Landau","year":"2013","journal-title":"Ann Neurol"},{"issue":"11","key":"10.14283\/jpad.2020.51_bib10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jalz.2018.01.013","article-title":"Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging","volume":"14","author":"Schindler","year":"2018","journal-title":"Alzheimer's Dement"},{"issue":"11","key":"10.14283\/jpad.2020.51_bib11","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer's disease concord with amyloid-\u03b2 PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimer's Dement"},{"issue":"3","key":"10.14283\/jpad.2020.51_bib12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3233\/JAD-160286","article-title":"Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid A\u03b242 and the Ratios of A\u03b2 Isoforms Using Low Protein Binding Tubes. Galimberti D, editor","volume":"53","author":"Vanderstichele","year":"2016","journal-title":"J Alzheimer's Dis"},{"issue":"3","key":"10.14283\/jpad.2020.51_bib13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF A \u03b2 42\/A \u03b2 40 and A \u03b2 42\/A \u03b2 38 ratios: better diagnostic markers of Alzheimer disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann Clin Transi Neurol"},{"issue":"1","key":"10.14283\/jpad.2020.51_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer's Disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"10.14283\/jpad.2020.51_bib15","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2967\/jnumed.114.142109","article-title":"Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: Concordance with visual image reads","volume":"55","author":"Thurfiell","year":"2014","journal-title":"J Nucl Med"},{"key":"10.14283\/jpad.2020.51_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuroimage.2013.01.015","article-title":"Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches","volume":"71","author":"Cohen","year":"2013","journal-title":"Neuroimage"},{"issue":"10","key":"10.14283\/jpad.2020.51_bib17","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/jamaneurol.2015.1633","article-title":"Comparison of visual and quantitative florbetapir F 18 positron emission tomography analysis in predicting mild cognitive impairment outcomes","volume":"72","author":"Schreiber","year":"2015","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.14283\/jpad.2020.51_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The Centiloid project: Standardizing quantitative amyloid plaque estimation by PET","volume":"1","author":"Klunk","year":"2015","journal-title":"Alzheimer's Dement"},{"issue":"2","key":"10.14283\/jpad.2020.51_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2018.09.001","article-title":"Multisite study of the relationships between antemortem [11 C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology","volume":"15","author":"La Joie","year":"2019","journal-title":"Alzheimer's Dement"},{"issue":"1","key":"10.14283\/jpad.2020.51_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","article-title":"Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers","volume":"11","author":"Salvado","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.14283\/jpad.2020.51_bib21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.14283\/jpad.2020.24","article-title":"The Future of Anti-Amyloid Trials","volume":"7","author":"Aisen","year":"2020","journal-title":"J Prev Alzheimer's Dis"},{"issue":"1","key":"10.14283\/jpad.2020.51_bib22","first-page":"46","article-title":"Amyloid and Tau Biomarkers in CSF","volume":"2","author":"Blennow","year":"2015","journal-title":"J Prev Alzheimer's Dis"},{"issue":"2","key":"10.14283\/jpad.2020.51_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.trci.2016.02.003","article-title":"The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease","volume":"2","author":"Molinuevo","year":"2016","journal-title":"Alzheimer's Dement (New York, N Y)"},{"issue":"4\u20135","key":"10.14283\/jpad.2020.51_bib24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clinbiochem.2013.12.024","article-title":"Biobanking of CSF: International standardization to optimize biomarker development","volume":"47","author":"Teunissen","year":"2014","journal-title":"Clin Biochem"},{"issue":"1","key":"10.14283\/jpad.2020.51_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13195-020-00587-5","article-title":"Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease","volume":"12","author":"Amadoru","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"10.14283\/jpad.2020.51_bib26","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1093\/brain\/aww160","article-title":"Pittsburgh compound B imaging and cerebrospinal fluid amyloid-\u03b2 in a multicentre European memory clinic study","volume":"139","author":"Leuzy","year":"2016","journal-title":"Brain"},{"issue":"12","key":"10.14283\/jpad.2020.51_bib27","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00259-017-3749-6","article-title":"18F-Florbetaben PET beta-amyloid binding expressed in Centiloids","volume":"44","author":"Rowe","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.14283\/jpad.2020.51_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 1995.pdf","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B."},{"issue":"1","key":"10.14283\/jpad.2020.51_bib29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13195-016-0233-7","article-title":"Unbiased estimates of cerebrospinal fluid \u03b2-amyloid 1\u201342 cutoffs in a large memory clinic population","volume":"9","author":"Bertens","year":"2017","journal-title":"Alzheimer's Res Ther"},{"key":"10.14283\/jpad.2020.51_bib30","first-page":"563","article-title":"Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project","volume":"10","author":"Willemse","year":"2018","journal-title":"Alzheimer's Dement Diagnosis, Assess Dis Monit"},{"issue":"8","key":"10.14283\/jpad.2020.51_bib31","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archneurol.2010.179","article-title":"Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people","volume":"67","author":"De Meyer","year":"2010","journal-title":"Arch Neurol"},{"issue":"4","key":"10.14283\/jpad.2020.51_bib32","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/brain\/aww015","article-title":"Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography","volume":"139","author":"Palmqvist","year":"2016","journal-title":"Brain"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724004059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724004059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:12:35Z","timestamp":1737339155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724004059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2274580724004059"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2020.51","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Analysis of Different Definitions of Amyloid-\u03b2 Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2020.51","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}